• vcard
202.772.8477
  • Education
    • Ph.D., Washington University in St. Louis, 2009, Molecular Microbiology and Microbial Pathogenesis
    • B.S., University of Wisconsin-Madison, 2003,

       

Corinne K. Cusumano received her Ph.D. in the field of molecular microbiology and microbial pathogenesis from Washington University. Her thesis work focused on the pathogenesis of uropathogenic E. coli in urinary tract infection. Specifically, Corinne investigated the role of adhesins in disease progression. Corinne also continued her post-doctoral work in this field, focusing on the development of novel therapeutics directed against adhesins to treat and prevent urinary tract infection. Working in this novel field gave Corinne experience in the fields of microbiology, immunology, molecular biology, protein chemistry, genetic engineering, biochemistry and confocal microscopy. 

Following her work at Washington University, Corinne worked as a consultant for a health care consulting firm. Her primary focus was oncology. During this time she assisted pharmaceutical companies with various aspects of drug development including pipeline development, primary market research, landscape assessment and forecasting of the market potential of novel drugs. Corinne joined Polsinelli in 2013 and concentrates her intellectual property work in the area of patent preparation and prosecution for biological, biochemical or biotechnological patents in the U.S. and abroad.  Her clients range from university tech transfer offices to small startups to established companies. Corinne has drafted and prosecuted patent applications in the field of oncology, neurodegenerative diseases, infectious diseases, cardiovascular diseases, gastrointestinal diseases, ophthalmology, diabetes, vaccines, sequencing, molecular biosensors and many more. As well as patents directed to novel compounds, antibodies, and enzymes for the treatment of urinary tract infections, cancer, and immune-mediated diseases. Corinne also assists with patentability, invalidity, freedom to operate, and due diligence efforts for intellectual property transactions.